Anupam Desai, MD
Hematology & Oncology · Boston, MANPI 1316126733
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by EMD Serono, Inc. at 58.4% of the total.
Across 15 payments — averaging $433.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$4K
- Amgen$2K
- Roche Products Limited$299
- E.r. Squibb & Sons, L.L.C.$298
- Springworks Therapeutics, Inc.$150
- F. Hoffmann-la Roche AG$46
Across 3 payments — averaging $25,878 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$66K
- Amgen$11K
What the payments were for
- Consulting fees$3,80058%
- Travel & lodging$1,87429%
- Food & beverage$83113%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 1 | $3,800 |
| Amgen | 5 | $1,913 |
| Roche Products Limited | 1 | $299 |
| E.r. Squibb & Sons, L.L.C. | 6 | $298 |
| Springworks Therapeutics, Inc. | 1 | $150 |
| F. Hoffmann-la Roche AG | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMLYGIC$1,503
- Non-Covered Product$299
- OGSIVEO$150
How this compares
$6,505 in reported general payments places this provider in the 65th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MekinistTrametinib Dimethyl Sulfoxide | 27 | $426,119 |
| TafinlarDabrafenib Mesylate | 26 | $377,844 |
| Levothyroxine Sodium | 28 | $301 |
| Oxycodone Hcl | 11 | $217 |
| Lorazepam | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.